Yang Fang-Fang, Gao Yu-Hai, Xi Hui-Rong, Li Wen-Yuan, Ma Hui-Ping, Chen Ke-Ming
Department of Orthopedics,Lanzhou General Hospital,Lanzhou 730050,China.
Department of Pharmacy,Lanzhou General Hospital,Lanzhou 730050,China.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2018 Aug 30;40(4):456-462. doi: 10.3881/j.issn.1000-503X.9912.
Objective To study the effect of the compound medicine of tanshinone 2A and resveratrol on peak bone mass in growing rats and to explore its possible mechanism,so as to explore anti-osteoporosis mechanisms of new traditional Chinese medicine (TCM) drugs. Methods Totally 40 1-month-old female Wistar rats were randomly divided into tanshinone 2A group,resveratrol group,compound group (tanshinone 2A and resveratrol),and normal control group,with 10 rats in each group. Body weight was measured once every two weeks,and the whole body bone mineral density was measured with dual-energy X-ray monthly. When the whole-body bone mineral density became statistically significant between medication groups and control group,all animals were sacrificed to determine the bone mineral density of vertebrae and right femoral bone. The biomechanical properties of femur and vertebrae were measured by AGS-X series universal test,then the bone morphology was analyzed with Fuchsin picric acid staining. Finally,the levels of tartrate-resistant acid phosphatase 5b and osteocalcin were measured with enzyme-linked immunosorbent assay.Results The body weights were not statistically significant among all groups (P>0.05). The whole-body bone mineral density showed no significant difference (P>0.05) after feeding for 1 month;however,two months later,it was significantly different between medication groups and control group;in particular,the whole-body (P=0.016),femoral (P=0.001),and vertebral bone mineral density (P=0.034),bone trabecular number (P=0.024),thickness (P=0.040),and area (P=0.038) were significantly increased in the compound group,along with the significantly decreased trabecular separation degree (P=0.032). Compared with the control group,the compound group had significantly increased osteocalcin (P=0.033) and tartrate-resistant acid phosphatase 5b (P=0.028) levels in serum.Conclusion The compound of tanshinone 2 A and resveratrol can improve the bone density and bone quality in rats,and such effect is higher than either tanshinone 2 A monomer or resveratrolmonomer.
目的 研究丹参酮ⅡA与白藜芦醇复方药物对生长期大鼠峰值骨量的影响并探讨其可能机制，以探寻新型中药抗骨质疏松的作用机制。方法 将40只1月龄雌性Wistar大鼠随机分为丹参酮ⅡA组、白藜芦醇组、复方组（丹参酮ⅡA与白藜芦醇）和正常对照组，每组10只。每两周测量一次体重，每月用双能X线测量全身骨密度。当用药组与对照组的全身骨密度出现统计学差异时，处死所有动物，测定腰椎和右侧股骨的骨密度。用AGS-X系列万能试验机测定股骨和腰椎的生物力学性能，然后用苦味酸品红染色分析骨形态。最后，用酶联免疫吸附测定法检测抗酒石酸酸性磷酸酶5b和骨钙素水平。结果 各组体重差异无统计学意义（P>0.05）。喂养1个月后，全身骨密度差异无统计学意义（P>0.05）；但2个月后，用药组与对照组有显著差异；尤其是复方组的全身（P=0.016）、股骨（P=0.001）和腰椎骨密度（P=0.034）、骨小梁数量（P=0.024）、厚度（P=0.040）和面积（P=0.038）显著增加，骨小梁分离度显著降低（P=0.032）。与对照组相比，复方组血清骨钙素（P=0.033）和抗酒石酸酸性磷酸酶5b（P=0.028）水平显著升高。结论 丹参酮ⅡA与白藜芦醇复方能提高大鼠的骨密度和骨质量，且该作用优于丹参酮ⅡA单体或白藜芦醇单体。
